script.reportAU
Vaccines

Human papillomavirus (hpv) types 16/18 vaccine

Brand: Cervarix

PBAC's latest decision on Human papillomavirus (hpv) types 16/18 vaccine: Recommended with restriction (2015). Considered for Prophylactic vaccination of females aged 12-13 years against cervical cancer and precancerous lesions associated with HPV-16 and HPV-18, using a 2-dose regimen instead of the previously listed 3-dose regimen.

PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2015
Submissions
1
2015 → 2015

Eligible population

Females aged 12-13 years (with some supportive immunogenicity data in 9-14 year olds and 15-25 year olds) receiving a 2-dose HPV-16/18 vaccine regimen for prevention of cervical cancer and precancerous lesions.

Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Immunogenicity (GMT, seroconversion)
Pivotal trial size
3,482 patients
Key trials
HPV-048, HPV-070, HPV-071, HPV-008, HPV-009, HPV-010
Comparator
Cervarix 3-dose and Gardasil 3-dose
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis used for Cervarix 2-dose vs Cervarix 3-dose; partial cost-effectiveness analysis for Cervarix 2-dose vs Gardasil 3-dose. No numeric ICER stated in the public text.

Similar precedents

Open on full dashboard →